An HTLV-I Transgenic Mouse Model: Role of the Tax Gene in Pathogenesis in Multiple Organ Systems
The human T-lymphotropic virus type I (HTLV-I) has been associated with a lymphoproliferative disease called adult T-cell leukemia/lymphoma (ATLL) (Poiesz et al. 1980; Yoshida et al. 1982; Hinuma et al. 1981; Kalyanaraman et al. 1982) and a neurodegenerative disease called tropical spastic paraparesis (TSP) (Gessain et al. 1985; Rodgers-Johnson et al. 1985; Bartholomew et al. 1986) or HTLV-I-associated myelopathy (HAM) (Osame et al. 1986a). These diseases appear to share few common clinical features. ATLL has a prolonged latency, but once established is frequently rapidly fatal (Broder et al. 1984). The disturbance consists of a monoclonal expansion of mature peripheral T cells each of which contains copies of retroviral sequences (Poiesz et al. 1980; Miyoshi et al. 1980; Yamamoto et al. 1981; Popovic et al. 1983; Chen et al. 1983; Yoshida et al. 1984). Death results from consequences of uncontrolled cellular proliferation and dysfunction. In contrast, the associated neurologic disease usually shows a shorter latency period and a slowly progressive course (Roman 1988; Osame et al. 1986a). Though variable degrees of HTLV-I-infected lymphocytic infiltration into the CNS may be seen in this disease, the cellular target for viral infection within the nervous system remains unclear (Jacobson et al. 1988). To study potential mechanisms of these disparate HTLV-I-induced diseases, we created a transgenic mouse model in which the tax gene (trans-activator of transcription) was introduced under control of the HTLV-I viral long-terminal repeat (LTR) promoter.
KeywordsTropical Spastic Paraparesis Cell Leukemia Virus Type Monoclonal Expansion Uncontrolled Cellular Proliferation Chloramphenicol Acetyl Transferase Reporter
Unable to display preview. Download preview PDF.
- Broder S, Jaffe ES, Blattner W, Gallo RC, Wong-Staal F, Waldman TA, DeVita VT (1984) T cell lymphoproliferative syndrome associated with human T cell leukemia/lymphoma virus. Ann Intern Me 100: 543–557Google Scholar
- Mora CA, Garruto RM, Brown P, Guiroy D, Morgan OSC, Rodgers-Johnson P, Ceroni M, Yanagihara R, Goldfarb LG, Gibbs CJ, Gajdusek DC (1988) Seroprevalence of antibodies to HTLV-I in patients with chronic neurological disorders other than tropical spastic paraparesis. Ann Neurol 23 (Suppl): S192 - S195PubMedCrossRefGoogle Scholar
- Nerenberg MI, Wiley CA (1989) The HTLV-I tax protein induces tissue specific disorders of neoplasia and atrophy in transgenic mice. Am. J. Pathol., in press.Google Scholar
- Osame MK, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M (1986a) HTLVI associated myelopathy, a new clinical entity. Lancet is 1932–1033Google Scholar
- Weiss R (1982) In: Weiss R, Teich N, Varmus H, Coffin J (eds) RNA tumor viruses. Cold Spring Harbor Laboratory, New York, pp 1205–1281Google Scholar